Yazen's weight control success: 60 tonnes shed!

Patients at the digital healthcare provider Yazen have now collectively shed 60 tonnes, thereby contributing to both improved personal health and reduced healthcare costs through fewer comorbidities.

Since its launch at the turn of the year, the digital healthcare provider Yazen has commenced treatment for approximately 7,500 patients. These patients have collectively lost over 60 tonnes and reduced their waistlines by more than half a kilometre. Each patient gains access to a doctor, YazenCoach, dietitian, personal trainer, and psychologist through Yazen's app. This, in combination with modern GLP-1 medications, has proven to be highly effective in assisting chronically overweight individuals in their weight loss journey. Patients typically lose an average of 1.5 kilograms per week at the start of treatment. After 3 months, the average weight loss is 8%, and after 6 months, it reaches 12%.

"Being able to prescribe modern anti-obesity medications in conjunction with lifestyle changes has dramatically changed how we can treat patients with obesity. It has proven to be highly effective and creates entirely new opportunities in the fight against chronic obesity," says Martin Carlsson, researcher, physician, and specialist in endocrinology/diabetology, and the founder of Yazen.

Every kilogram of excess weight lost benefits both the individual and society as a whole. In addition to its impact on quality of life, obesity serves as the foundation for a range of serious diseases. Severely overweight individuals often develop type 2 diabetes, cardiovascular diseases, and have an increased risk of developing cancer. Two million Swedes take blood pressure medications, and one million take medications to lower cholesterol levels. Obesity is now recognized as a chronic disease that shortens life expectancy. Individuals who are 40 years old with a BMI over 40 have only a 50% chance of reaching the age of 70. Many die prematurely. Any weight loss within this demographic is significant for both the individual and society.

Meet a patient: Linda reclaimed her lifeWith a surgically stiffened back, a weight of 150 kilograms, and an even heavier sense of shame, Linda Sedenborg, a 45-year-old from Borås, had long suffered from severe obesity.

"Since I was 18, I've battled with my weight and tried various diets. In 2014, it had gotten so bad that I had to undergo abdominal surgery, removing a significant portion of my stomach," says Linda Sedenborg.

However, after losing weight following the surgery, Linda began to regain it. It was during this time that she got in touch with Yazen and started medical treatment with the medication semaglutide.

"The medication worked, and my hunger decreased. It was an absolutely fantastic feeling," says Linda.

In October 2022, Linda started using Ozempic, and along with Saxenda, she has lost 30 kilograms so far. Today, she weighs 90 kilograms and is still on her way down.

"In addition to medications, I gained access to a team of specialists digitally. This way, I receive support to truly change my life, both in terms of diet, exercise, and mental attitude. I have a chronic disease, but it's a treatable one, and now I can maintain my new weight in the long term. I hope that more people with obesity receive help," says Linda Sedenborg.

For more information and to get in touch with local patients:Christina Waller Sterner, Marketing Manager at 767 66 9067

About Yazen - Physician-Led Medical Weight ManagementYazen has developed an effective medical treatment in line with the latest medical recommendations, which includes medications and lifestyle advice provided by doctors, psychologists, dietitians, specially trained YazenCoachers, and medically trained personal trainers for ongoing treatment with regular follow-up appointments. The service is intended for those who are overweight, with a BMI over 30 or a BMI over 27 with complications caused by obesity. The average BMI for Yazen's patients at the start of treatment is 34.

Start your weight loss journey with Yazen today

Everything you need to do is to create an account and answer some questions about your health

Get Started
Get Started
Get Started

More news

Popular drug linked to reduced dementia risk in elderly with diabetes

Study shows GLP-1 agonists reduce dementia risk in elderly with type 2 diabetes. Findings from KI highlight potential benefits for diabetes treatment

WHO: Medical Product Alert: Fake Ozempic (semaglutide)

Medical Product Alert: Fake Ozempic (semaglutide) Detected in Americas and Europe

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely